



CONTINUING MEDICAL EDUCATION INFORMATION

MISSION

The purpose of the American Academy of Dermatology (AAD) CME Program is to provide members with opportunities for life-long learning and assistance in fulfilling their maintenance of certification and licensure requirements, thereby promoting excellence in the provision of dermatologic care.

DEFINITION OF CONTINUING MEDICAL EDUCATION

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. *Source: www.accme.org*

COMMERCIAL BIAS

Content or format in a CME activity or its related materials that promotes the products or business lines of an ineligible company. As described in the Standards for Integrity and Independence in Accredited Continuing Education, providers are responsible for protecting learners from commercial bias and marketing. In addition to preventing influence from ineligible companies, the Standards prohibit faculty from actively promoting or selling products or services that serve their professional or financial interests. *Source: www.accme.org*

SCIENTIFIC ASSEMBLY COMMITTEE

** As of the November 19, 2021 planning meeting.*

Kathryn Schwarzenberger, MD
Tammie Ferringer, MD
David Ozog, MD
Robert Sidbury, MD, MPH
Hensin Tsao, MD
Marta Van Beek, MD, Secretary-Treasurer
Daniel Bennett, Assistant Secretary-Treasurer
Kenneth Tomecki, MD, President
Mark Kaufmann, MD, President-Elect

Bryan Anderson, MD, Chair, Council on Education
Julia Wu, MD, Chair, Education Research Committee
Kim Yancey, MD, Chair, Named Lectureship Task Force
Paola Pasquali, MD, Chair, International Affairs Committee
Dhwani Mehta, MD, Young Physician's Committee Representative

STATEMENT OF NEED

The AAD Innovation Academy is planned to comprehensively address the nine content areas within the Dermatologic Core Curriculum and provide dermatologists and other dermatology health care professionals with high quality educational opportunities for the optimization of dermatologic knowledge, competence and performance.

TARGET AUDIENCE

The target audience of the AAD Innovation Academy are dermatologists and others involved in the delivery of dermatologic care.

GLOBAL LEARNING OBJECTIVES

This comprehensive activity provides learners with opportunities to:

- Review and apply basic knowledge and skills in medical dermatology, dermatologic surgery, pediatric dermatology, and dermatopathology.
- Update their knowledge about recent advances in the diagnosis, management and treatment of diseases of the skin, hair, nails, and mucous membranes.
- Assess the relationship of evidence-based diagnostic approaches and therapies with new dermatologic treatment developments.
- Self assess current practice management skills and develop strategies for improving these skills.
- Apply new procedural skills into everyday practice.

NOTE: Each session has its own specific learning objectives which are included within each session description in the Innovation Academy Mobile App.

DISCLOSURES

PLANNER DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

The following Scientific Assembly Committee members and staff have no financial relationship(s) with ineligible companies relevant to the content of this CME activity:

- Brian Anderson, MD
- Daniel D. Bennett, MD
- Tammie Ferringer, MD
- Cari Lamberg
- Tammi Matillano
- Dhvani S. Mehta, MD
- Timothy A. Moses, CMP
- Jennifer Thompson
- Kenneth J. Tomecki, MD
- Julia Wu, MD
- Candi Zabiegala

The following Scientific Assembly Committee members and staff do have a financial relationship(s) with ineligible companies to be disclosed to learners:

Planner	Commercial Interest	Role
Mark D. Kaufmann, MD, FAAD	Biofrontera AG	Consultant / Fees
	Castle Biosciences, Inc	Consultant / Fees
	Clarify Medical, Inc.	Consultant / Fees
	DermTech Inc.	Advisory Board / Fees
	Galderma USA	Consultant / Fees
	Klara/Goderma, Inc.	Consultant / Stock Options
	MediWound	Consultant / Fees
	Modernizing Medicine	Consultant / Stock
	MoleSafe, Inc.	Other / Fees, Other / Stock
	Ortho Dermatologics	Consultant / Fees
	Rise Healthcare Tech	Advisory Board / Stock Options
	SciBASE	Consultant / Fees
	Sun Pharmaceutical Industries, Ltd.	Consultant / Fees
	UCB	Consultant / Fees
Verrica Pharmaceuticals, Inc	Consultant / Fees	
David M. Ozog, MD, FAAD	Biofrontera AG	Investigator / Grants/Research Funding
	Galderma USA	Investigator / Grants/Research Funding
	miRagen Therapeutics, Inc.	Investigator / Grants/Research Funding

	Regeneron	Speaker / Honoraria
	Sanofi Genzyme	Speaker / Honoraria
	Sciton, Inc.	Investigator /Equipment
Paola Pasquali, MD	Dermosight	Advisory Board / No Compensation Received
	Springer Science & Business Media	Other / Patent royalties or other compensation for Intellectual Property Rights
Kathryn Schwarzenberger, MD, FAAD	Pfizer Inc.	Data Safety Monitoring Board / Fees
	Pretel, Inc.	Founder / No Compensation Received
Hensin Tsao, MD, PhD, FAAD	Epiphany Dermatology	Advisory Board / Honoraria
	Lazarus AI	Consultant / Honorarium
	Massachusetts General Hospital	Employee / Salary
	Ortho Dermatologics	Board of Directors / Honoraria
	UpToDate, Inc.	Other / Honoraria
Marta Jane Van Beek, MD, MPH, FAAD	AbbVie	Stockholder / No Compensation Received
	Becton Dickinson	Stockholder / No Compensation Received
	Johnson and Johnson	Stockholder / No Compensation Received
	Moderna Therapeutics	Stockholder / No Compensation Received
	Pfizer Inc.	Stockholder / No Compensation Received
	Regenx	Stockholder / No Compensation Received
	Vertex Pharmaceuticals, Inc.	Stockholder / No Compensation Received
Kim B. Yancey, MD FAAD	UpToDate, Inc	Other / Honorarium

PRIOR TO THE START OF THIS ACTIVITY, ALL RELEVANT FINANCIAL RELATIONSHIPS WERE MITIGATED

FACULTY DISCLOSURE OF FINANCIAL RELATIONSHIP(S)

It is the policy of AAD that all faculty participating in a CME-certified activity are required to disclose to AAD and to learners all financial relationships they have with any ineligible companies in any amount occurring within the past 24 months that could create a conflict of interest¹. Typically, such relationships would be with companies that whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The intent of this disclosure is not to prevent participation in CME-certified educational activities by individuals with a relevant financial relationship with an ineligible company(s), but rather to provide learners with information on which they can make their own determination whether or not said relationship(s) influenced the content of the educational activity.

Faculty disclosure information is located within the description of each individual session in the Innovation Academy Mobile App. Faculty have been asked to also make a verbal disclosure at the start of their presentations supplemented by a disclosure slide in order to verify the accuracy of the disclosure information posted in the session and ensure their disclosure information is shared with the learners PRIOR to the presentation taking place.

RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Independence and Integrity in Accredited Continuing Education, the American Academy of Dermatology has implemented mechanisms, prior to the planning and

¹ **Conflict of Interest:** When an individual's interests are aligned with those of an ineligible company the interests of the individual are in "conflict" with the interests of the public. *Source: www.accme.org*

implementation of this CME activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CME activity.

UNAPPROVED USE DISCLOSURE

The American Academy of Dermatology requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label (not approved for the indications being discussed), unlabeled (not approved for any indications), experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these products/procedures. If you have questions, contact the medical affairs department of the manufacturer for the most recent approval information. Faculty for this activity will be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

INDEPENDENCE IN CME

The mission of the Academy's continuing medical education program is to improve patient care and health care outcomes by maintaining, developing and enhancing medical knowledge, patient care, interpersonal and communication skills and professionalism. As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME) and in support of this mission, the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias.

The Academy employs several strategies to ensure these standards will be met. The planning committee members submit and consider their own disclosure information and recuse themselves from planning educational activities should they have conflicts related to the subject area presented. When developing an educational program, the planning committee reviews applications and disclosure of interest forms, along with needs assessment and evaluative data from past activities in order to develop programming. Potential participants are sent detailed guidelines that provide direction on necessary components to ensure independence in continuing medical education activities and to resolve conflict.

CONTENT VALIDATION

Academy-sponsored educational activities are designed to promote improvements or quality in health care and not promote a specific proprietary business interest or a commercial interest. Presentations and related materials must be based on scientific methods generally accepted by the medical community.

Presentations should be evidence-based and discuss the validity of the evidence upon which they base the opinion(s) (see Sackett et al, BMJ 1996;312:71-2). This ensures the audience that the recommendations are supported by the evidence and contributes to management of any potential conflicts of interest. Further, if the presentation includes discussion of unlabeled or investigational use of a commercial product, this also must be disclosed to the participants. CME must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality.

If CME educational material or content includes trade names, trade names from several companies should be used where available, as opposed to using trade names from just a single company. Educational materials such as slides, abstracts, and handouts cannot contain any advertising or product-group messages.

OUTCOMES MEASUREMENT

Several methods of evaluation are utilized in assessing the educational program. Session directors, speakers, and attendees are all given the opportunity to evaluate the educational content and speaker performance. Included in this process are measures to rate the success of the Academy's policies regarding independence in continuing medical education activities with particular focus on the absence of commercial bias.

In addition, the Academy may review speaker presentations. These data are only used to determine effectiveness of the Academy's policies and procedures regarding disclosure. Should it be determined that a member of the Academy's educational program violated the Academy's "Policy to Ensure Independence in Continuing Medical Education," the individual may not be asked to participate in future educational programs.

DISCLAIMER

The American Academy of Dermatology is not responsible for statements made by faculty. Statements or opinions expressed in this program reflect the views of the faculty and do not reflect the official policy of the American Academy of Dermatology. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to the diagnostic, management and treatment options of a specific patient's medical condition.

COMMERCIAL SUPPORT DISCLOSURE

The following ineligible company provided commercial support for the 2022 Innovation Academy at the time of publication:

The following ineligible company provided in-kind commercial support for the 2022 Innovation Academy at the time of publication:

George Teimann & Co.
Janssen Biotech, Inc

Tools for Derm Lab Sessions
Meeting Resources to Enhance the Educational Sessions

ACCREDITATION

The American Academy of Dermatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA CATEGORY 1 CREDIT™ DESIGNATION

The American Academy of Dermatology designates this live activity for a maximum of **22.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

WHAT YOU NEED TO DO TO CLAIM CME CREDIT

CME credit is awarded based on participation in the learning activities. CME credits can be claimed online at www.aad.org/evals or in the meeting mobile app. Credit is calculated on a ¼-hour basis and will be reflected on member transcripts within two weeks after the meeting.